Clinical Trial Update: Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) [Phase 2]

View source ↗

Summary

Phase 2 trial of NBMI for atypical Parkinsonian disorders (Progressive Supranuclear Palsy and Multiple System Atrophy) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy
• Progressive Supranuclear Palsy

Drugs mentioned

• NBMI

Snippet

Sponsor: EmeraMed | Conditions: Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Status: COMPLETED